Last reviewed · How we verify
gemcitabine, cisplatin and bevacizumab
This combination uses gemcitabine and cisplatin as chemotherapy agents to damage cancer cell DNA, while bevacizumab blocks tumor blood vessel formation to inhibit cancer growth.
This combination uses gemcitabine and cisplatin as chemotherapy agents to damage cancer cell DNA, while bevacizumab blocks tumor blood vessel formation to inhibit cancer growth. Used for Advanced or metastatic non-small cell lung cancer, Ovarian cancer, Bladder cancer.
At a glance
| Generic name | gemcitabine, cisplatin and bevacizumab |
|---|---|
| Also known as | Avastin |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Combination chemotherapy with anti-angiogenic monoclonal antibody |
| Target | DNA (gemcitabine, cisplatin); VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Gemcitabine is a nucleoside analog that disrupts DNA synthesis in rapidly dividing cells. Cisplatin is a platinum-based alkylating agent that cross-links DNA and triggers apoptosis. Bevacizumab is a monoclonal antibody targeting VEGF that prevents angiogenesis, starving tumors of blood supply. Together, these agents provide dual chemotherapy with anti-angiogenic support.
Approved indications
- Advanced or metastatic non-small cell lung cancer
- Ovarian cancer
- Bladder cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Nephrotoxicity
- Neuropathy
- Bleeding
- Hypertension
Key clinical trials
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: